Enrichment designs using placebo nonresponders

被引:4
|
作者
Benda, Norbert [1 ,2 ]
Haenisch, Britta [1 ,3 ,4 ]
机构
[1] Fed Inst Drugs & Med Devices BfArM, Res Dept, Bonn, Germany
[2] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
[3] German Ctr Neurodegenerat Dis DZNE, Populat Hlth Sci, Bonn, Germany
[4] Univ Bonn, Ctr Translat Med, Bonn, Germany
关键词
drug approval; enrichment design; placebo response; sequential parallel design; MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; CLINICAL-TRIALS; ZIPRASIDONE MONOTHERAPY; 12-WEEK; SYMPTOMS; EFFICACY; OUTCOMES; THERAPY;
D O I
10.1002/pst.1992
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Enrichment designs that select placebo nonresponders have gained much attention during the last years in areas with high placebo response rates, eg, in depression. Proposals were made that re-randomize patients who did not respond to placebo during a first study phase as the sequential parallel design (SPD). This design uses in a second phase an enriched patient population where the treatment effect is expected to be more pronounced. This may be problematic if an effect in the overall population is claimed. Proposals were made to combine the treatment effects in the overall population from study phase 1 and the enriched population from study phase 2, alleviating but not solving the issue of a potential selection bias. This paper shows how this bias corresponding to the effect difference between the overall population and the enriched population depends on the variability of a potential subject-by-treatment interaction. Sample sizes are given, which lead to a significant result in the combining test with a given probability if actually the average effect in the overall population is zero. If, on the other hand, no subject-by-treatment interaction is given, the enrichment is shown to be inefficient. We conclude that enrichment designs using placebo nonresponders are not able to claim a positive average effect in the overall population if a subject-by-treatment interaction cannot be excluded. It cannot be used to demonstrate positive efficacy in the overall population in a pivotal phase III trial but may be used in early phases to demonstrate varying treatment effects between patients.
引用
收藏
页码:303 / 314
页数:12
相关论文
共 50 条
  • [41] Stochastic optimization of adaptive enrichment designs for two subpopulations
    Fisher, Aaron
    Rosenblum, Michael
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (05) : 966 - 982
  • [42] Can placebo controls reduce the number of nonresponders in clinical trials? A power-analytic perspective
    Leon, AC
    CLINICAL THERAPEUTICS, 2001, 23 (04) : 596 - 603
  • [43] Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study
    Altamura, Alfredo Carlo
    Serati, Marta
    Buoli, Massimiliano
    Dell'Osso, Bernardo
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2011, 26 (04) : 201 - 205
  • [44] Optimal, two-stage, adaptive enrichment designs for randomized trials, using sparse linear programming
    Rosenblum, Michael
    Fang, Ethan X.
    Liu, Han
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 2020, 82 (03) : 749 - 772
  • [45] Remarks on designs enriching for placebo non-responders
    Rosenkranz, Gerd K.
    CLINICAL TRIALS, 2016, 13 (03) : 338 - 343
  • [46] Novel designs and paradigms to study the placebo response in gastroenterology
    Enck, Paul
    Chae, Younbyoung
    Elsenbruch, Sigrid
    CURRENT OPINION IN PHARMACOLOGY, 2017, 37 : 72 - 79
  • [47] Statistical Considerations for Noninferiority Trial Designs Without Placebo
    Hung, H. M. James
    Wang, Sue-Jane
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2013, 5 (03): : 239 - 247
  • [48] Identifying nonresponders to asthma therapy using leukocyte parameters
    Velthove, Karin J.
    Bracke, Madelon
    Schweizer, Rene C.
    ten Berg, Maarten J.
    Leufkens, Hubert G. M.
    van Solinge, Wouter W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S145 - S145
  • [49] Population Enrichment Designs: Case Study of a Large Multinational Trial
    Mehta, Cyrus R.
    Gao, Ping
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (04) : 831 - 845
  • [50] IMPROVING PROBABILITIES OF CORRECT INTERIM DECISION IN POPULATION ENRICHMENT DESIGNS
    Goette, Heiko
    Donica, Margarita
    Mordenti, Giacomo
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (05) : 1020 - 1038